11/19
08:32 am
alzn
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital [Yahoo! Finance]
High
Report
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital [Yahoo! Finance]
11/19
08:00 am
alzn
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
High
Report
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
11/12
01:24 pm
alzn
Alzamend Neuro (NASDAQ:ALZN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Alzamend Neuro (NASDAQ:ALZN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
9/25
08:06 am
alzn
Alzamend Neuro (NASDAQ:ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $45.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Alzamend Neuro (NASDAQ:ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $45.00 to $42.00. They now have a "buy" rating on the stock.